AbbVieXTER:4AB +3.40%79 OCF Margin % is 25.52% as of Mar. 2026, which is 35% below its 10-year median of 39.23. GuruFocus rates XTER:4AB with a GF Score™ of 79/100 and a GF Value™ of €185.20 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 959 Drug Manufacturers companies, AbbVie ranks better than 94.68% on this metric.
OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. AbbVie's Cash Flow from Operations for the
three
months ended in Mar. 2026 was €3,312 Mil. AbbVie's Revenue for the
three
months ended in Mar. 2026 was €12,977 Mil. Therefore, AbbVie's OCF Margin % for the quarter that ended in Mar. 2026 was 25.52%.
The historical rank and industry rank for AbbVie's OCF Margin % or its related term are showing as below:
XTER:4AB'
s OCF Margin % Range Over the Past 10 Years
Min: 27.46 Med: 39.23 Max: 42.97
Current: 33.75
During the past 13 years, the highest OCF Margin % of AbbVie was 42.97%. The lowest was 27.46%. And the median was 39.23%.
XTER:4AB's OCF Margin % is ranked better than 94.68% of 959
companies
in the Drug Manufacturers industry
Industry Median: 9.94
vs XTER:4AB: 33.75
AbbVie OCF Margin % Related Terms
AbbVie OCF Margin % Historical Data
* Premium members only.
The historical data trend for AbbVie's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XTER:4AB vs MRK, JNJ, AMGN: OCF Margin % Comparison
For the Drug Manufacturers - General subindustry, AbbVie's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AbbVie OCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, AbbVie's OCF Margin % distribution charts can be found below:
* The bar in red indicates where AbbVie's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AbbVie (XTER:4AB) has a OCF Margin % of 25.52% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on AbbVie and its competitors. This is 35% below median its historical median of 39.23. Over the past decade, AbbVie's OCF Margin % has ranged from 27.46 to 42.97. According to the industry distribution chart, AbbVie ranks #51 out of 959 companies in the Drug Manufacturers industry, placing it in the top 5.3%.
Is AbbVie's OCF Margin % too high?
AbbVie's current OCF Margin % of 25.52% is 35% below median its 10-year median of 39.23. Over the past 10 years, this metric has ranged from a low of 27.46 to a high of 42.97. The Drug Manufacturers industry median OCF Margin % is 9.94. AbbVie's value of 25.52% is 156.7% above this industry median. Based on the distribution chart, AbbVie ranks #51 out of 959 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, AbbVie has a GF Score™ of 79/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AbbVie's OCF Margin % compare to MRK and JNJ?
According to the Drug Manufacturers industry distribution chart, AbbVie ranks #51 out of 959 companies for OCF Margin %. This places AbbVie in the top 5% of its industry — outperforming the majority of peers. The industry median OCF Margin % is 9.94. AbbVie's value of 25.52% is 156.7% above this benchmark. Historically, AbbVie's own OCF Margin % has ranged from 27.46 to 42.97 over the past decade. While the company's 10-year median is 39.23 vs. the industry median of 9.94, AbbVie has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Drug Manufacturers company?
The median OCF Margin % among Drug Manufacturers companies is 9.94, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AbbVie's current OCF Margin % of 25.52% is 156.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on AbbVie and its competitors. For the Drug Manufacturers industry, the median OCF Margin % is 9.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AbbVie's current OCF Margin % is 25.52%, which is 35% below median its own 10-year median of 39.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AbbVie stock overvalued right now?
Based on GuruFocus' analysis, AbbVie (XTER:4AB) is currently considered Modestly Overvalued. The stock's GF Value™ is €185.20, compared to a current price of €213.00 — trading 15% above its estimated fair value. The current OCF Margin % is 25.52%, which is 35% below median its 10-year median of 39.23 and 156.7% above the Drug Manufacturers industry median of 9.94. AbbVie's overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For AbbVie (XTER:4AB), the current OCF Margin % is 25.52% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AbbVie (XTER:4AB) Overvalued in 2026?
Based on GuruFocus' analysis, AbbVie stock appears to be overvalued.
The current stock price of €213.00 is trading 15% above its estimated GF Value™ of €185.20.
GuruFocus considers AbbVie to be Modestly Overvalued.
Key valuation signals for XTER:4AB:
OCF Margin %: 25.52% (35% below median its 10-year median of 39.23)
GF Value™: €185.20 vs. price of €213.00 (15% above fair value)
Industry Position: 156.7% above the Drug Manufacturers median (#51 of 959)
No single metric tells the full story. See the XTER:4AB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
79GF Score
Get the complete analysis for XTER:4AB
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTER:4AB has been successfully added to your 
